20 Sep

Cannabis Roundup: HEXO, CRON, CURA, and ACB

WRITTEN BY Rajiv Nanjapla

Today, CNCB reported that Chinese trade officials were returning home from the US ahead of schedule. The news appears to have led to a fall in the broader US equity markets. At 2:10 PM ET, the S&P 500 Index and the Dow Jones Industrial Average were both down 0.3%. Cannabis ETFs were also trading in the red.

Cannabis ETFs

The ETFMG Alternative Harvest ETF (MJ) and the Horizons Marijuana Life Sciences Index ETF (HMMJ) were down 0.7% and 0.9%, respectively. Today, the stock performances of cannabis players were mixed.

HEXO receives a “buy” rating

Today, MKM Partners initiated coverage on HEXO (HEXO) with a “buy” rating and a price target of 12 Canadian dollars. MKM Partners’ “buy” rating appears to have led to a rise in HEXO’s stock price. At 2:10 PM, the stock was up 11.3%. After its release of its third-quarter earnings results on June 12, HEXO stock was down 38.2% as of September 19. During the quarter, the company reported a sequential fall in its revenue, while its net losses were wider than in its second quarter.

Cronos was up 1.2%

Today, Cronos Group (CRON) received a “neutral” rating from MKM Partners. Yesterday, the company announced a manufacturing partnership with MediPharm Labs. According to the deal, MediPharm will provide filling and packaging services for Cronos Group’s vaporizer devices. At 2:10 PM, the company was up 1.2%. YTD, its stock has fallen 5.4%.

Curaleaf falls approximately 5%

Today, MarketWatch reported that MKM Partners had initiated coverage on Curaleaf Holdings (CURA) (CURLF) with a “sell” rating. MKM Partners’ rating appears to have led Curaleaf stock to fall. At 2:10 PM ET, the company was trading 5.1% lower. However, the company’s stock price has risen 23.4% since it reported its second-quarter earnings results on August 27. Although Curaleaf’s second-quarter performance was below analysts’ expectations, management’s bullish outlook for fiscal 2020 drove the company’s stock price.

Aurora Cannabis falls over 2%

Today, MKM Partners initiated coverage on Aurora Cannabis (ACB) with a “sell” rating and a price target of 5 Canadian dollars. MKM Partners’ sell rating appears to have led to a fall in the company’s stock price. At 2:10 PM ET, its stock was down 2.6% from yesterday’s closing price.

The stock has been facing downward pressure since the company reported its fourth-quarter earnings results on September 11. It’s lost 19.7% of its value since then. Aurora’s lower-than-expected revenue in the fourth quarter appears to have led to the fall in its stock price.

Latest articles

The total refiners capacity in the US is around 18.8 million barrels per calendar day. The refinery utilization rate in 2018 was 93%.

Today's Snap earnings (SNAP) are a textbook example of how irrational, or at least unpredictable, market reactions can be.

On October 15, Aphria reported its Q1 earnings. Although Aphria's revenue came in lower than expected, its EBITDA and EPS beat analysts’ expectations.

Back-to-back dismal quarterly performance and a downbeat outlook have kept analysts increasingly cautious about FedEx's (FDX) growth prospects.

Texas Instruments (TXN) reported disappointing Q3 earnings and guidance. Its revenue fell 11.5% YoY to $3.77 billion, missing the estimate by 1.3%.

On October 22, Sprint announced that its True Mobile 5G service covers 16 million people in nine cities. That day, Sprint fell 1.1% and closed at $6.35.